Gyrus Capital is an investment firm that focuses on transformational investments in industries addressing societal and environmental needs, aimed at long-term sustainable growth.

Gyrus Capital

Gyrus Capital | 2,553 followers on LinkedIn. Sector-focused transformational investments | Gyrus is a private equity firm dedicated to transformational investments. We focus on sectors with strong, sustainable growth and investment opportunities where we can leverage our sector focus to support management to drive change and unlock value. 

Gyrus is based in Geneva, Switzerland.

Hannah Tobin

Cédric Perlet

Author, company director and charity trustee (not always in that order...)

Charles Spicer

Chairman of the Board CORCYM, FISSO, 3D-SIDE, DYVERTO. Non-Executive Director NEO MEDICAL.

Davide Bianchi

🔔 We’re expanding our team at Gyrus Capital We’re pleased to welcome Luigi Dufour and Bianca Bonetti to our executive team as we continue to grow in the #healthcare and #sustainability sectors. Their extensive backgrounds in private equity, innovation, and strategic planning will be invaluable as we focus on corporate carve-outs in the €50-500 million segment. These additions mark a key moment for Gyrus as we strengthen our capabilities, particularly in #Italy , and continue driving our strategic initiatives forward. #GyrusCapital #Healthcare #Sustainability #TeamExpansion #StrategicGrowth

We are delighted to announce that the Gyrus Capital Fund II has invested in Neo Medical , a pioneering Swiss technology company in spine surgery. We are excited to support Neo Medical’s vision for growth.

Congratulations dss+ on the acquisition of Infrata

Gyrus is delighted to welcome Dr Klaus Lun as the new CEO of LRE Medical. He brings over 20 years of experience in the life sciences, biotech and diagnostics industries. We look forward to him joining the LRE team in November. To learn more, visit https://gyrus.info/4f0K1fH

Congratulations dss+ on being named one of the best managed businesses in Switzerland!

We are delighted to announce that Gyrus Capital has entered into a binding agreement to sell Intellera Consulting, an Italian consultancy firm operating in the public administration and healthcare sectors, to Accenture. Read more here: https://gyrus.info/3THh3HV

Congratulations on the achievements last year and looking forward to seeing further impact delivered in 2024!

Intellera enhances its offerings with the acquisition of Spanish research and consulting firm, PredictBy

Congratulations to portfolio company Retail Consult on being recognised as a Great Place to Work in Portugal

Essential Pharma adds to its portfolio with its first rare disease product acquisition - the European rights to Colobreathe®, an inhaled medication used in Cystic Fibrosis.

GYRU

COM:GYRUSCAPITAL

Gyrus Capital

Financials Not Available